Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Tubach

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
Joint Bone Spine|June 16, 2009
Patient acceptable symptomatic state (PASS)Thao Pham, Florence Tubach
Joint Bone Spine|December 7, 2005
Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibsPhilippe Ravaud, Florence Tubach
BMJ (Clinical Research Ed.)|March 19, 2005
Managing osteoarthritis of the knee: conclusions about use of NSAIDs are misleadingFlorence Tubach, P Ravaud, B Giraudeau
Journal of Clinical Epidemiology|May 6, 2004
Natural history and prognostic indicators of sciaticaFlorence Tubach, Julien Beauté, Annette Leclerc
Journal of Clinical Epidemiology|January 9, 2009
The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimatesFlorence Tubach, Bruno Giraudeau, Philippe Ravaud
Journal of Clinical Epidemiology|November 27, 2010
Systematic review reveals heterogeneity in definition of a clinically relevant difference in painAdeline Ruyssen-Witrand, Florence Tubach, Philippe Ravaud
Therapie|August 20, 2011
Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologiesFlorence Tubach, Véronique Lamarque-Garnier, Anne Castot, et al.
Therapie|July 10, 2016
[Not Available]Florence Tubach, Véronique Lamarque-Garnier, Anne Castot, et al.
Journal of Clinical Epidemiology|May 28, 2017
Overfitting in propensity score model: a commentary on "propensity score model overfitting led to inflated variance of estimated odds ratios" by Schuster et alDavid Hajage, Florence Tubach, Yann De Rycke
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis TrialAntoine Vanier, Xavier Mariette, Florence Tubach, et al.
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
Joint Bone Spine|June 16, 2009
Patient acceptable symptomatic state (PASS)Thao Pham, Florence Tubach
Joint Bone Spine|December 7, 2005
Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibsPhilippe Ravaud, Florence Tubach
BMJ (Clinical Research Ed.)|March 19, 2005
Managing osteoarthritis of the knee: conclusions about use of NSAIDs are misleadingFlorence Tubach, P Ravaud, B Giraudeau
Journal of Clinical Epidemiology|May 6, 2004
Natural history and prognostic indicators of sciaticaFlorence Tubach, Julien Beauté, Annette Leclerc
Journal of Clinical Epidemiology|January 9, 2009
The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimatesFlorence Tubach, Bruno Giraudeau, Philippe Ravaud
Journal of Clinical Epidemiology|November 27, 2010
Systematic review reveals heterogeneity in definition of a clinically relevant difference in painAdeline Ruyssen-Witrand, Florence Tubach, Philippe Ravaud
Therapie|August 20, 2011
Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologiesFlorence Tubach, Véronique Lamarque-Garnier, Anne Castot, et al.
Therapie|July 10, 2016
[Not Available]Florence Tubach, Véronique Lamarque-Garnier, Anne Castot, et al.
Journal of Clinical Epidemiology|May 28, 2017
Overfitting in propensity score model: a commentary on "propensity score model overfitting led to inflated variance of estimated odds ratios" by Schuster et alDavid Hajage, Florence Tubach, Yann De Rycke
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis TrialAntoine Vanier, Xavier Mariette, Florence Tubach, et al.
Pageof 27